Study of the Immune Response in Colon Adenocarcinoma (IMCO)
Etude de la réponse Immunitaire Dans l'adénocarcinome Colique
Sponsor: Innate Pharma
Listed as NCT03015038, this observational or N/A phase trial focuses on Colon Adenocarcinoma and remains completed. Sponsored by Innate Pharma, it has been updated 14 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Completed
-
Apr 2025 — Jan 2026 [monthly]
Completed
Status: Unknown → Completed
-
Sep 2024 — Apr 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Mar 2024 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
▶ Show 9 earlier versions
-
Dec 2021 — Mar 2024 [monthly]
Active Not Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting
Status: Not Yet Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting
-
Jun 2018 — Nov 2020 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Not Yet Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Innate Pharma
- Institut National de la Santé Et de la Recherche Médicale, France
For direct contact, visit the study record on ClinicalTrials.gov .